Chemoresistance in breast tumors

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Chemotherapeutic resistance is a major obstacle in cancer treatment, occurring either initially or acquired during therapy.
• Multidrug resistance (MDR) is characterized by cross-resistance to structurally dissimilar drugs, often linked to P170 glycoprotein overexpression.
• P170 acts as an energy-dependent efflux pump, reducing intracellular drug accumulation and contributing to treatment failure.

Purpose of the Study:

• To review the current understanding of chemo-resistance mechanisms in cancer.
• To explore the role of P170 glycoprotein and other factors in multidrug resistance.
• To discuss strategies for overcoming drug resistance and identify potential therapeutic targets.

Main Methods:

• Review of in vitro and in vivo studies on multidrug resistance mechanisms.
• Analysis of the role of P170 glycoprotein, topoisomerases, and other enzymes.
• Examination of resistance mechanisms for adriamycin, methotrexate, and cyclophosphamide.

Main Results:

• P170 glycoprotein overexpression is a key mechanism in MDR, but 'atypical' MDR suggests other factors are involved.
• Changes in topoisomerases, protein kinases, and glutathione S-transferase activity can also confer pleiotropic resistance.
• Methotrexate resistance involves dihydrofolate reductase amplification or transport defects; cyclophosphamide resistance is linked to glutathione S-transferase and aldehyde dehydrogenase.

Conclusions:

• Understanding diverse chemo-resistance mechanisms, including P170-dependent and independent pathways, is crucial for effective cancer therapy.
• Identifying resistance markers and developing targeted interventions are essential for overcoming drug resistance.
• Further research into the regulation of resistance-related genes may reveal novel therapeutic strategies against drug-resistant tumors.